INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm

Moore Law is investigating potential shareholder claims against Aardvark Therapeutics over allegations that it overstated the safety and clinical prospects of lead metabolic-disease candidate ARD-101. Aardvark paused its Phase 3 HERO trial following cardiac observations in February, triggering a 56.2% share-price decline to $5.47, and the FDA subsequently imposed a full clinical hold in May, followed by a further 32.1% decline to $4.57. The investigation adds litigation and governance risk following material clinical and regulatory setbacks for the company’s lead asset.

Analysis

This law-firm notice is not an independent clinical or regulatory development and should not itself alter intrinsic value. Its practical effect is to keep governance and disclosure risk in the foreground, potentially raising D&O costs and complicating any future equity financing; for a pre-revenue issuer, the financing overhang matters more than prospective damages. The key valuation variable remains whether a path to resolving the FDA hold exists without a materially redesigned program, additional toxicology work, or a prolonged dose-ranging restart.

Near term, AARD is structurally vulnerable to low-liquidity volatility, tax-loss selling, and any indication that cash runway does not extend through the regulatory remediation process. Over 1-3 months, the decisive catalyst is FDA correspondence or a company update quantifying the required package, expected resubmission timing, and remaining cash burn—not additional plaintiff-firm announcements. Over 6-18 months, a delayed or terminated program would improve the competitive position of Soleno Therapeutics (SLNO) in hyperphagia-related rare disease markets, although the commercial overlap is incomplete and should not be treated as a direct revenue transfer.

The contrarian consideration is that litigation headlines are usually immaterial after the underlying adverse events are public, while a credible regulatory path can trigger an outsized rebound from depressed levels. That asymmetry argues against maintaining an unhedged fundamental short in AARD: clinical-stage names can re-rate sharply on a hold modification, partnership, or financing that removes survival risk. The bearish thesis is falsified by explicit FDA alignment, a defined restart timeline, and funded runway through the next meaningful efficacy readout.

Key Decisions for Investors

• No new directional AARD position on this litigation release; treat it as a monitoring event rather than a catalyst. Reassess only after management discloses FDA-required remediation, cash runway, and expected timing for a hold-resolution submission.
• Avoid a naked AARD short over the next 1-3 months despite weak fundamentals: borrow availability, low-float dynamics, and binary FDA/news risk can create a sharp squeeze. If expressing downside after a relief rally, use defined-risk put spreads only if option liquidity and implied volatility are acceptable.
• Watch SLNO as a relative beneficiary of prolonged competitive delay, but require evidence that AARD's target population and commercial positioning overlap sufficiently before initiating a pair trade. AARD regulatory discontinuation or a delay beyond 12 months would strengthen this thesis; a rapid AARD restart would negate it.
• Set an alert for any financing announcement: an equity raise at a steep discount or an at-the-market program would validate dilution risk and likely pressure AARD, while non-dilutive capital or a strategic partnership would materially weaken the downside case.